Although it’s a highly personal question, and only my business, I will say that, upon stumbling, by pure accident, across some very substantial information through my contacts in the medical/Pharma/retail industry in March 2017.
Someone was speaking, I was listening, I did not interrupt or ask a question. As I said recently, I know a little because I listen a lot. I felt, no, I knew, as I was picking myself off the floor, that the information should not be disclosed to anyone and I made a difficult decision, that day, to neither buy or sell one more share of BIEL. I have not wavered since, although I will say it has been with no small amount of disappointment.......
I think today of what I heard and I smile, sleepin like a baby.
USPTO patented, FDA OTC Cleared for the foot and knee, with many more to come. People in Washington know about BIEL and ActiPatch and I believe the U.S., although behind the UK OTC full retail clearance a few years ago and the UK NHS national health insurance full coverage in England, Ireland, Scotland and Wales this month, the USA is coming quickly like a Tsunami.....
Retail, online, Pharmacies, Hospitals, Medicare, Medicaid, The Blues......and >140 MILLION Americans suffering with diagnosed chronic pain or with acute pain every day. Add Allay for severe menstrual cramping and pain, with a trial to be completed in a couple of days, a migraine trial to be completed very soon and the BIEL journey will only get better.
I have speculated my belief recently that BIEL is profitable right now and it has a busy pipeline. It makes no sense whatsoever to me that BIEL management is not building much more momentum......YKW......Tsunami
News 
Market Data 
Discover 
AI
